HRP20190201T1 - Modificirana anti-tgf-beta protutijela i ulomci koji vežu antigen - Google Patents
Modificirana anti-tgf-beta protutijela i ulomci koji vežu antigenInfo
- Publication number
- HRP20190201T1 HRP20190201T1 HRP20190201TT HRP20190201T HRP20190201T1 HR P20190201 T1 HRP20190201 T1 HR P20190201T1 HR P20190201T T HRP20190201T T HR P20190201TT HR P20190201 T HRP20190201 T HR P20190201T HR P20190201 T1 HRP20190201 T1 HR P20190201T1
- Authority
- HR
- Croatia
- Prior art keywords
- tgf
- parts
- modified anti
- antibody antigen
- beta antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001134—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361776430P | 2013-03-11 | 2013-03-11 | |
| EP14779440.8A EP2971048B1 (en) | 2013-03-11 | 2014-03-11 | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
| PCT/US2014/023274 WO2014164709A2 (en) | 2013-03-11 | 2014-03-11 | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190201T1 true HRP20190201T1 (hr) | 2019-03-22 |
Family
ID=51659302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190201TT HRP20190201T1 (hr) | 2013-03-11 | 2014-03-11 | Modificirana anti-tgf-beta protutijela i ulomci koji vežu antigen |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9783604B2 (https=) |
| EP (2) | EP2971048B1 (https=) |
| JP (1) | JP6495884B2 (https=) |
| KR (1) | KR102258457B1 (https=) |
| CN (1) | CN105229160B (https=) |
| AR (1) | AR095240A1 (https=) |
| AU (2) | AU2014249051B2 (https=) |
| BR (1) | BR112015021595A2 (https=) |
| CA (1) | CA2904847C (https=) |
| CY (1) | CY1121412T1 (https=) |
| DK (1) | DK2971048T3 (https=) |
| ES (2) | ES2845215T3 (https=) |
| HR (1) | HRP20190201T1 (https=) |
| HU (1) | HUE042020T2 (https=) |
| IL (1) | IL241404B (https=) |
| LT (1) | LT2971048T (https=) |
| MX (1) | MX365385B (https=) |
| PL (1) | PL2971048T4 (https=) |
| PT (1) | PT2971048T (https=) |
| RU (1) | RU2681502C2 (https=) |
| SG (2) | SG11201507279XA (https=) |
| SI (1) | SI2971048T1 (https=) |
| TR (1) | TR201901415T4 (https=) |
| TW (2) | TWI613216B (https=) |
| UY (1) | UY35384A (https=) |
| WO (1) | WO2014164709A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2921805C (en) | 2013-08-22 | 2023-03-07 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
| EP4400516A1 (en) | 2014-12-15 | 2024-07-17 | The Regents of the University of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| EP3234120B1 (en) | 2014-12-15 | 2025-09-03 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| HK1256638A1 (zh) | 2015-08-04 | 2019-09-27 | Acceleron Pharma Inc. | 用於治疗骨髓增生性病症的方法 |
| DK3368571T5 (da) * | 2015-10-30 | 2024-09-30 | Univ California | Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf |
| ES2904553T3 (es) * | 2015-10-30 | 2022-04-05 | Hoffmann La Roche | Fragmentos de anticuerpo modificados con bisagra y procedimientos de preparación |
| WO2017201036A1 (en) | 2016-05-17 | 2017-11-23 | Genentech, Inc. | Stromal gene signatures for diagnosis and use in immunotherapy |
| GB201610044D0 (en) | 2016-06-08 | 2016-07-20 | Ucb Biopharma Sprl | Antibodies |
| JP2019533003A (ja) * | 2016-08-11 | 2019-11-14 | プレシセラ，インコーポレイテッド | ＴＧＦ−βアンタゴニストコンジュゲート |
| JP2019530440A (ja) | 2016-09-02 | 2019-10-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物 |
| LT3628049T (lt) | 2017-05-04 | 2023-08-25 | Acceleron Pharma Inc. | Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai |
| ES2984919T3 (es) | 2017-11-06 | 2024-10-31 | Hoffmann La Roche | Procedimientos diagnósticos y terapéuticos para el cáncer |
| MX2021000347A (es) * | 2018-07-11 | 2021-04-19 | Scholar Rock Inc | Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos. |
| BR112022003412A2 (pt) | 2019-08-28 | 2022-05-24 | Chugai Pharmaceutical Co Ltd | Anticorpos anti-tgf-beta 1 latente de espécies cruzadas e métodos de uso |
| CN114728072A (zh) | 2019-10-23 | 2022-07-08 | 库尔生物制药有限公司 | TGF-β多肽 |
| TWI867190B (zh) * | 2020-03-19 | 2024-12-21 | 美商建南德克公司 | 同功型選擇性抗-TGF-β抗體及其使用方法 |
| US20220119513A1 (en) * | 2020-06-08 | 2022-04-21 | Zoetis Services Llc | Anti-tgfb antibodies and therapeutic uses thereof |
| WO2022115611A1 (en) | 2020-11-25 | 2022-06-02 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
| US20240101675A1 (en) * | 2021-01-21 | 2024-03-28 | Biolojic Design Ltd. | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof |
| CN112851819B (zh) * | 2021-01-25 | 2023-08-11 | 华中科技大学同济医学院附属同济医院 | 结合小鼠PD-L1和TGF-β的双特异性抗体及其制备方法与应用 |
| EP4291227A2 (en) * | 2021-02-15 | 2023-12-20 | Takeda Pharmaceutical Company Limited | Cell therapy compositions and methods for modulating tgf-b signaling |
| CN113480645B (zh) * | 2021-07-16 | 2022-11-11 | 甘肃中科博瑞生物工程有限公司 | 一种抗幽门螺旋杆菌重组抗体、制备方法及用途 |
| WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
| WO2024077166A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating lung cancer |
| WO2024077095A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating bladder cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571714A (en) * | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| JP4124815B2 (ja) | 1991-10-31 | 2008-07-23 | ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ | ＴＧＦ−β型受容体ｃＤＮＡおよびその用途 |
| US6008011A (en) | 1991-10-31 | 1999-12-28 | Whitehead Institute For Biomedical Research | TGF-β type II receptor cDNAs |
| RU2157406C2 (ru) * | 1993-08-10 | 2000-10-10 | Биофарм Гезелльшафт Цур Биотехнологишен Энтвиклунг Фон Фармака Мбх | НОВЫЙ ФАКТОР РОСТА/ДИФФЕРЕНЦИАЦИИ TGF-β-СЕМЕЙСТВА |
| IL110589A0 (en) | 1993-08-10 | 1994-11-11 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF- beta family |
| GB9601081D0 (en) * | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| CA2301166A1 (en) | 1997-07-24 | 1999-02-04 | Yuan-Peng Zhang | Liposomal compositions for the delivery of nucleic acid catalysts |
| WO2000040227A2 (en) | 1999-01-05 | 2000-07-13 | University Of Utah | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| US7763580B2 (en) | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| WO2001066140A1 (en) | 2000-03-09 | 2001-09-13 | Genzyme Corporation | Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| AU2003209308A1 (en) | 2002-01-22 | 2003-09-02 | Genzyme Corporation | Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection |
| EP1620128A1 (en) | 2003-04-30 | 2006-02-01 | Genzyme Corporation | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
| WO2006086469A2 (en) | 2005-02-08 | 2006-08-17 | Genzyme Corporation | Antibodies to tgfbeta |
| EP1948675B1 (en) | 2005-10-25 | 2014-07-30 | The Johns Hopkins University | Methods and compositions for the treatment of marfan syndrome and associated disorders |
| KR101516823B1 (ko) * | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
| WO2007121233A1 (en) | 2006-04-12 | 2007-10-25 | Genzyme Corporation | Methods of treating autoimmune diseases |
| DK2083863T3 (da) | 2006-10-03 | 2015-06-22 | Genzyme Corp | Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi |
| US20120294868A1 (en) | 2009-04-24 | 2012-11-22 | Edwards James R | Anti-tgf-beta induction of bone cell function and bone growth |
| ME02464B (me) | 2010-03-12 | 2017-02-20 | Genzyme Corp | Kombinovana terapija za lečenje raka dojke |
| MY165160A (en) | 2010-09-01 | 2018-02-28 | Genzyme Corp | TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS |
-
2014
- 2014-03-11 PT PT14779440T patent/PT2971048T/pt unknown
- 2014-03-11 DK DK14779440.8T patent/DK2971048T3/en active
- 2014-03-11 EP EP14779440.8A patent/EP2971048B1/en active Active
- 2014-03-11 LT LTEP14779440.8T patent/LT2971048T/lt unknown
- 2014-03-11 RU RU2015143156A patent/RU2681502C2/ru active
- 2014-03-11 KR KR1020157027607A patent/KR102258457B1/ko active Active
- 2014-03-11 HU HUE14779440A patent/HUE042020T2/hu unknown
- 2014-03-11 TR TR2019/01415T patent/TR201901415T4/tr unknown
- 2014-03-11 SG SG11201507279XA patent/SG11201507279XA/en unknown
- 2014-03-11 TW TW103108359A patent/TWI613216B/zh active
- 2014-03-11 HR HRP20190201TT patent/HRP20190201T1/hr unknown
- 2014-03-11 AU AU2014249051A patent/AU2014249051B2/en active Active
- 2014-03-11 UY UY0001035384A patent/UY35384A/es not_active Application Discontinuation
- 2014-03-11 EP EP18181808.9A patent/EP3415633B1/en active Active
- 2014-03-11 CA CA2904847A patent/CA2904847C/en active Active
- 2014-03-11 MX MX2015012541A patent/MX365385B/es active IP Right Grant
- 2014-03-11 AR ARP140100849A patent/AR095240A1/es not_active Application Discontinuation
- 2014-03-11 ES ES18181808T patent/ES2845215T3/es active Active
- 2014-03-11 ES ES14779440T patent/ES2713505T3/es active Active
- 2014-03-11 CN CN201480026283.5A patent/CN105229160B/zh active Active
- 2014-03-11 SG SG10201707021RA patent/SG10201707021RA/en unknown
- 2014-03-11 SI SI201431071T patent/SI2971048T1/sl unknown
- 2014-03-11 US US14/773,950 patent/US9783604B2/en active Active
- 2014-03-11 WO PCT/US2014/023274 patent/WO2014164709A2/en not_active Ceased
- 2014-03-11 PL PL14779440T patent/PL2971048T4/pl unknown
- 2014-03-11 JP JP2016501191A patent/JP6495884B2/ja active Active
- 2014-03-11 TW TW106136054A patent/TWI664979B/zh active
- 2014-03-11 BR BR112015021595A patent/BR112015021595A2/pt not_active IP Right Cessation
-
2015
- 2015-09-09 IL IL241404A patent/IL241404B/en active IP Right Grant
-
2017
- 2017-08-07 US US15/670,631 patent/US10730936B2/en active Active
-
2018
- 2018-05-10 AU AU2018203261A patent/AU2018203261B2/en active Active
-
2019
- 2019-01-31 CY CY20191100139T patent/CY1121412T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190201T1 (hr) | Modificirana anti-tgf-beta protutijela i ulomci koji vežu antigen | |
| HUS2200041I1 (hu) | Anti-CD3 antitestek és alkalmazási eljárások | |
| IL290972A (en) | Anti-vista antibodies and fragments | |
| DK3683235T3 (da) | Anti-IL-33-antistoffer og anvendelser deraf | |
| DK3026062T3 (da) | Anti-pd-1-antistof og anvendelse deraf | |
| IL246287B (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
| DK3027209T3 (da) | Anti-Activin A-antistoffer og anvendelser deraf | |
| DK3480215T5 (da) | Anti-her2-antistof og konjugat deraf | |
| LT3071597T (lt) | Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai | |
| PL2948477T3 (pl) | Konstrukty przeciwciała dla cdh19 i cd3 | |
| PL3148579T3 (pl) | Przeciwciała anty-gitr i sposoby ich zastosowania | |
| ME03489B (me) | Molekuli antitijela na tim-3 i njihove upotrebe | |
| HUE040234T2 (hu) | Humanizált anti-CD134 (OX40) antitestek és felhasználásaik | |
| DK3381943T3 (da) | Anti-kit-antistoffer og anvendelser deraf | |
| DK3019240T3 (da) | Anti-komplementfaktor C1Q antistoffer og anvendelser deraf | |
| DK3079719T3 (da) | ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3086807T3 (da) | Antistoffer og fremgangsmåder til anvendelse | |
| DK3004162T3 (da) | Anti-væg-teichoin-antistoffer og konjugater | |
| SI3052192T1 (sl) | Nevtralizarijoča protitelesa proti-influenci A in njihove uporabe | |
| IL244590A0 (en) | Anti-epcam antibodies and methods of use | |
| DK2864359T3 (da) | Anti-cd26-antistoffer og anvendelser deraf | |
| EP3074772C0 (en) | APPARATUS AND METHODS FOR SELECTING ANTIBODY | |
| DK2951208T3 (da) | Anti-cd83 antistoffer og anvendelse deraf | |
| FR3002228B1 (fr) | Anticorps monoclonal et utilisations | |
| TH1501005356A (th) | แอนติ-il-33 แอนติบอดีและการใช้ของมัน |